CRISPR-Cas9-Mediated Gene Therapy in Neurological Disorders

Mol Neurobiol. 2022 Feb;59(2):968-982. doi: 10.1007/s12035-021-02638-w. Epub 2021 Nov 23.

Abstract

Neurological disorders are primarily diseases with sophisticated etiology that are always refractory and recrudescent. The major obstruction to effective therapies for neurological disorders is the poor understanding of their pathogenic mechanisms. CRISPR-Cas9 technology, which allows precise and effective gene editing in almost any cell type and organism, is accelerating the pace of basic biological research. An increasing number of groups are focusing on uncovering the molecular mechanisms of neurological disorders and developing novel therapies using the CRISPR-Cas9 system. This review highlights the application of CRISPR-Cas9 technology in the treatment of neurological disorders, including Alzheimer's disease, amyotrophic lateral sclerosis and/or frontotemporal dementia, Duchenne muscular dystrophy, Dravet syndrome, epilepsy, Huntington's disease, and Parkinson's disease. Hopefully, it will improve our understanding of neurological disorders and give insights into future treatments for neurological disorders.

Keywords: CRISPR-Cas; Gene therapy; Genome editing; Neurological disorders.

Publication types

  • Review

MeSH terms

  • CRISPR-Cas Systems* / genetics
  • Gene Editing
  • Genetic Therapy
  • Humans
  • Muscular Dystrophy, Duchenne*